Malignant Hyperthermia - PowerPoint PPT Presentation

malignant hyperthermia n.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
Malignant Hyperthermia PowerPoint Presentation
Download Presentation
Malignant Hyperthermia

play fullscreen
1 / 9
Malignant Hyperthermia
220 Views
Download Presentation
avidan
Download Presentation

Malignant Hyperthermia

- - - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

  1. Malignant Hyperthermia By Aaron Denson 1/30/13

  2. Why do Anesthesiologist Care? • This rare but life-threatening condition is usually triggered by exposure to certain drugs used for general anesthesia, specifically the volatile anesthetic agents and the neuromuscular blocking agent, succinylcholine.

  3. Mechanism • In 50–70% of cases, malignant hyperthermia is due to a mutation of the ryanodine receptor (type 1), located on the sarcoplasmic reticulum. • This mutation results in a drastic increase in intracellular calcium levels and muscle contraction.

  4. Mechanism (cont’d) • The process of sequestering this excess Ca2+ consumes large amounts of ATP, and generates the hyperthermia that is the hallmark of the disease. • The muscle cell is damaged by depletion of ATP and possibly the high temperatures, and cellular constituents "leak" into the circulation, including K+, myoglobin, creatine, phosphate and creatine kinase.

  5. Signs/Symptoms • Early masseter muscle contracture following administration of succinylcholine, a rise in end-tidal carbon dioxide concentration (despite increased minute ventilation), unexplained tachycardia, and muscle rigidity • Other: Hyperthermia (late), Tachypnea, Acidosis, Rhabdomyolysis • The symptoms usually develop within one hour after exposure to trigger substances, but may even occur several hours later in rare instances

  6. Suceptability testing • The standard procedure is the "caffeine-halothane contracture test", CHCT. • Has a high sensitivity (97 percent) and specificity (78 percent).

  7. Treatment • IV Dantrolene, the only known antidote • Discontinuation of triggering agents • Supportive therapy directed at correcting hyperthermia, acidosis, and organ dysfunction. • Treatment must be instituted rapidly on clinical suspicion of the onset of malignant hyperthermia

  8. Prognosis • In the 1970s, mortality was greater than 80%; with the current management, however, mortality is now less than 5%

  9. Thanks